Results 61 to 70 of about 89,305 (304)

Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice. [PDF]

, 2019
Approximately 15-40% of all cancers develop metastases in the central nervous system (CNS), yet few therapeutic options exist to treat them. Cancer therapies based on monoclonal antibodies are widely successful, yet have limited efficacy against CNS ...
Chen, Irvin SY, Guan, Xin, Kamata, Masakazu, Kranz, Emiko, Lee, YooJin, Liu, Chaoyong, Liu, Yang, Lu, Yunfeng, Martinez-Maza, Otoniel, Qin, Meng, Sun, Guibo, Sun, Xiaobo, Vinters, Harry V, Wang, Lan, Wen, Jing, Widney, Daniel, Wu, Di, Xu, Duo   +17 more
core  

Antibody Conjugation and Formulation [PDF]

, 2019
In an era where ultra-high antibody concentrations, high viscosities, low volumes, auto-injectors, and long storage requirements are already complex problems with the current unconjugated monoclonal antibodies on the market the formulation demands for ...
Alves, Nathan J.
core   +1 more source

pH/ROS‐Responsive Injectable Hydrogel Co‐Loaded with B7‐H3 Blocker and NETs Suppressor Boosts OSCC Synergistic Immunotherapy

Advanced Science, EarlyView.
A pH/ROS‐dual‐responsive injectable hydrogel, formed by dynamic boronic ester and Schiff base crosslinking, co‐delivers enoblituzumab (B7‐H3 blocker) and Cl‐amidine (NETs suppressor). Via localized intratumoral delivery, it synergistically reprograms the immunosuppressive tumor microenvironment, overcomes T cell infiltration barriers, restores ...
Huan Li, Yun Li, Yating Hu, Yanbing Yao, Yaodong He, Jing Li, Jiaqi Tang, Zhenyan Zhao, Yan Wang, Yulun He, Xiaolong Zhang, Xinjie Yang, Jianhua Wei   +12 more
wiley   +1 more source

Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. [PDF]

, 2016
BackgroundOnly Clostridium botulinum strain IBCA10-7060 produces the recently described novel botulinum neurotoxin type H (BoNT/H). BoNT/H (N-terminal two-thirds most homologous to BoNT/F and C-terminal one-third most homologous to BoNT/A) requires ...
Arnon, Stephen S, Barash, Jason R, Conrad, Fraser, Fan, Yongfeng, Lou, Jianlong, Marks, James D   +5 more
core   +1 more source

Human Monoclonal Antibodies Neutralizing Human Cytomegalovirus

Journal of General Virology, 1987
Hybridomas producing human monoclonal antibodies (MAbs) against human cytomegalovirus (CMV) were generated by fusion of human spleen cells and mouse myeloma cells. Two of the six MAbs obtained neutralized viral infectivity even at concentrations lower than 1 microgram/ml. One MAb required complement for neutralization but the other did not.
Y, Masuho, Y, Matsumoto, T, Sugano, S, Fujinaga, Y, Minamishima   +4 more
openaire   +2 more sources

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto, Deborah Silverman, Tongxin Xie, Shamima Akhter, Nicole R. Vaughn, Adewale Adebayo, Kala Chand Debnath, Shorook Naara, Shajedul Islam, Erik Knutsen, Emily Lorin Ashkin, Simone Anfossi, Sara Leahey, Patrick Hwu, Sebastien Talbot, Erica K Sloan, Robert Saddawi‐Konefka, Roberto Rangel, Jeffrey N. Myers, George A. Calin, Moran Amit   +20 more
wiley   +1 more source

Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors. [PDF]

, 2019
The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in application to multiple cancers, as a monotherapy and ...
Le, Catherine T, Murphy, William J
core   +1 more source

Adipocyte‐Derived Exosomal miR‐5099 Mitigates M1 Macrophage Polarization and Adipose Inflammation via c‐Met/NF‐κB Axis to Improve Metabolic Health

Advanced Science, EarlyView.
Celastrol upregulates adipocyte‐derived exosomal miR‐5099, suppressing the macrophage c‐Met/NF‐κB axis to mitigate pro‐inflammatory M1 polarization and adipose inflammation. These miR‐5099‐enriched exosomes also act as endocrine signals targeting the liver, muscle, and adipocytes to significantly enhance systemic insulin sensitivity.
Ping Tang, Lixin Tai, Hongxia Xu, Dongliang Zhu, Jiajia Li, Hao Feng, Jinghui Cui, Shuhai Lin, Li‐jun Di, Li Wang   +9 more
wiley   +1 more source

A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms

Frontiers in Molecular Biosciences, 2020
As human Tau undergoes pathologically relevant post-translational modifications when expressed in yeast, the use of humanized yeast models for the generation of novel Tau monoclonal antibodies has previously been proven to be successful.
Joke Verelst, Nick Geukens, Sabiha Eddarkaoui, Dorien Vliegen, Elien De Smidt, Joëlle Rosseels, Vanessa Franssens, Sofie Molenberghs, Cindy Francois, Erik Stoops, Maria Bjerke, Maria Bjerke, Sebastiaan Engelborghs, Sebastiaan Engelborghs, Mohamed Laghmouchi, Sofie Carmans, Luc Buée, Eugeen Vanmechelen, Joris Winderickx, Debby Thomas   +19 more
doaj   +1 more source

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources